Sponsor study identifier
Secondary identifiers
observational
75
1 country
1
Study Start
January 3, 2019
Actual (reported)Primary Completion
November 18, 2020
Actual (reported)Study Completion
November 18, 2020
Actual (reported)Background: Candida can cause infections. The most common kind of Candida at clinics is C albicans. But other kinds have increased at clinics too. Researchers want to review the records of people who were in previous NIH studies who had Candida. They want to find out what risk factors are associaated with this infection. Objective: To study the factors that are associated with Candida fungemia to develop. The factors are clinical features, diagnoses, and previous antifungal therapy. Eligibility: People who were in prior NIH studies and had Candida Design: Researchers will review the records of 62 NIH participants. The records are from 2004 to 2017. They will look at data such as blood test results, diagnosis, and treatments. Researchers will only reach out to participants if they get approval from a review board. This research will probably not reveal data that would be important to participants health. But if it does, researchers will try to contact those participants. Data will be stored in secure computers. They will be stored with a code that only the study team can link to a participant.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 18, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 3, 2019
Actual (reported)January 31, 2019
Actual (reported)February 1, 2019
Actual (reported)November 18, 2020
Actual (reported)November 18, 2020
Actual (reported)The objective of this protocol is to characterize the clinical features, underlying diagnoses, previous antimicrobial therapy, and previous antifungal therapy associated with the development of Candida fungemia, as well as the enrichment of n...
The objective of this protocol is to characterize the clinical features, underlying diagnoses, previous antimicrobial therapy, and previous antifungal therapy associated with the development of Candida fungemia, as well as the enrichment of non-albicans species of Candida.
Duration of study
Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
Patients who had Candida species grown from blood cultures drawn at the National Institutes of Health from 2004 until 2017.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892, United States
Michail S Lionakis, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
75 participants (actual enrollment reported by the registry).
First Submitted
January 31, 2019
First Posted
February 1, 2019
Study Start
January 3, 2019
Actual (reported)Primary Completion
November 18, 2020
Actual (reported)Study Completion
November 18, 2020
Actual (reported)Last Updated
November 27, 2020
Record last verified: 2020-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: